Although neoadjuvant immunotherapy for melanoma has produced encouraging results, the data have been constrained by a relatively brief follow-up period, with the majority of studies reporting two-year outcomes. This study’s objective was to assess the long-term effects of neoadjuvant and adjuvant PD-1( programmed cell death receptor 1 ) inhibition on stage III / IV melanoma patients.